• Celladon Corp., of San Diego, raised $10 million in the second close of its venture capital financing. The company originally raised $43 million in February from Pfizer Venture Investments, Lundbeckfon Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development Corp. and Venrock Associates. The second tranche brought the total to $53 million and added new investors MPM Capital and LSP Life Sciences Partners into the syndicate. Proceeds will support enzyme replacement therapy Mydicar for heart failure.

• Egalet Ltd., of Malvern, Pa., raised $14.3 million in a Series B financing. Investors in the financing included CLS Capital, Atlas Venture, Omega Funds, Sunstone Capital and Index Ventures. Proceeds will support development of abuse-resistant pain drugs using Egalet's tablet erosion technology. (See BioWorld Today, March 15, 2006.)

• Retrophin LLC, of New York, raised $4 million in a Series A financing led by MSMB Capital, the hedge fund run by the biotech's CEO, Martin Shkreli. Proceeds will support a proof-of-concept study with RE-021 for focal segmental glomerulosclerosis as well as preclinical work on RE-001 for Duchene's muscular dystrophy. (See BioWorld Today, March 12, 2012.)